Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.

Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A.

Eur Urol. 2020 Feb;77(2):180-188. doi: 10.1016/j.eururo.2019.09.027. Epub 2019 Oct 9.

PMID:
31606332
2.

Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.

Boehm K, Larcher A, Beyer B, Tian Z, Tilki D, Steuber T, Karakiewicz PI, Heinzer H, Graefen M, Budäus L.

Eur Urol. 2016 Jun;69(6):1038-43. doi: 10.1016/j.eururo.2015.07.051. Epub 2015 Aug 10.

PMID:
26272236
3.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

4.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.

5.

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A.

BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5.

6.

Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.

Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T.

BJU Int. 2011 Nov;108 Suppl 2:51-6. doi: 10.1111/j.1464-410X.2011.10687.x.

7.

External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

Tiberi D, Rodrigues G, Pickles T, Morris J, Crook J, Martin AG, Cury F, Catton C, Lukka H, Warner A, Taussky D.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):94-100. doi: 10.5489/cuaj.4084.

8.

A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.

Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, Shariat SF, Suardi N, Francesco M, Alberto B, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI.

World J Urol. 2017 Feb;35(2):189-197. doi: 10.1007/s00345-016-1863-x. Epub 2016 Jun 11.

PMID:
27289238
9.

Complementary role of the Memorial Sloan Kettering Cancer Center nomogram to the American Joint Committee on Cancer system for the prediction of relapse of major salivary gland carcinoma after surgery.

Chou WC, Chang KP, Lu CH, Chen MF, Cheng YF, Yeh KY, Wang CH, Lin YC, Yeh TS.

Head Neck. 2017 May;39(5):860-867. doi: 10.1002/hed.24702. Epub 2017 Feb 2.

PMID:
28152230
10.

Do prostate cancer nomograms give accurate information when applied to European patients?

Turo R, Forster JA, West RM, Prescott S, Paul AB, Cross WR.

Scand J Urol. 2015 Feb;49(1):16-24. doi: 10.3109/21681805.2014.920415. Epub 2014 Jun 2.

PMID:
24882277
11.

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.

Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC.

Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.

PMID:
28988753
12.

Validation of the memorial Sloan-Kettering Cancer Center nomogram to predict disease-specific survival after R0 resection in a Chinese gastric cancer population.

Chen D, Jiang B, Xing J, Liu M, Cui M, Liu Y, Wang Z, Chen L, Yang H, Zhang C, Yao Z, Zhang N, Ji J, Qu H, Su X.

PLoS One. 2013 Oct 17;8(10):e76041. doi: 10.1371/journal.pone.0076041. eCollection 2013.

13.

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.

Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.

PMID:
25466945
14.

External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.

Ishizaki F, Hoque MA, Nishiyama T, Kawasaki T, Kasahara T, Hara N, Takizawa I, Saito T, Kitamura Y, Akazawa K, Takahashi K.

Jpn J Clin Oncol. 2011 Nov;41(11):1259-64. doi: 10.1093/jjco/hyr136. Epub 2011 Sep 22.

PMID:
21940731
15.

Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.

Punnen S, Freedland SJ, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR.

Eur Urol. 2014 Jun;65(6):1171-7. doi: 10.1016/j.eururo.2013.03.058. Epub 2013 Apr 8.

16.

Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.

Donovan MJ, Khan FM, Powell D, Bayer-Zubek V, Cordon-Cardo C, Costa J, Eastham J, Scardino P.

BJU Int. 2012 Jan;109(1):40-5. doi: 10.1111/j.1464-410X.2011.10398.x. Epub 2011 Jul 19.

17.

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DYF, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.

Lancet Oncol. 2014 Dec;15(13):1521-1532. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13.

18.

Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy.

Zanelli E, Giannarini G, Cereser L, Zuiani C, Como G, Pizzolitto S, Crestani A, Valotto C, Ficarra V, Girometti R.

J Magn Reson Imaging. 2019 Nov;50(5):1604-1613. doi: 10.1002/jmri.26743. Epub 2019 Apr 7.

PMID:
30957321
19.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

20.

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.

Canter DJ, Reid J, Latsis M, Variano M, Halat S, Rajamani S, Gurtner KE, Sangale Z, Brawer M, Stone S, Bardot S.

Eur Urol. 2019 Mar;75(3):515-522. doi: 10.1016/j.eururo.2018.10.028. Epub 2018 Oct 31.

Supplemental Content

Support Center